Revolution Medicines priced a $1.5 billion follow-on offering and accompanying convertible notes only days after reporting Phase 3 top-line results for daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The financing—positioned as the largest follow-on in biopharma history—reflects investor appetite for RAS-targeted oncology after efficacy readouts renewed credibility in difficult-to-treat PDAC. The company’s ability to attract both equity and debt capital quickly after clinical momentum highlights a market shift toward “event-driven” funding, where Phase 3 catalysts can unlock scale financing for late-stage development and expansion of the pipeline. For the sector, the deal sets a high bar for valuation and funding access for next-wave oncology programs tied to biomarker-defined strategies.